These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1198 related articles for article (PubMed ID: 18179782)

  • 1. Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure.
    Veeraveedu PT; Watanabe K; Ma M; Palaniyandi SS; Yamaguchi K; Kodama M; Aizawa Y
    Biochem Pharmacol; 2008 Mar; 75(6):1322-30. PubMed ID: 18179782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of nonpeptide vasopressin V2 antagonist tolvaptan in rats with heart failure.
    Veeraveedu PT; Watanabe K; Ma M; Palaniyandi SS; Yamaguchi K; Suzuki K; Kodama M; Aizawa Y
    Biochem Pharmacol; 2007 Nov; 74(10):1466-75. PubMed ID: 17720144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of the V(2)-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats.
    Hirano T; Yamamura Y; Nakamura S; Onogawa T; Mori T
    J Pharmacol Exp Ther; 2000 Jan; 292(1):288-94. PubMed ID: 10604960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial.
    Gheorghiade M; Niazi I; Ouyang J; Czerwiec F; Kambayashi J; Zampino M; Orlandi C;
    Circulation; 2003 Jun; 107(21):2690-6. PubMed ID: 12742979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of tolvaptan on systemic and renal hemodynamic function in dogs with congestive heart failure.
    Onogawa T; Sakamoto Y; Nakamura S; Nakayama S; Fujiki H; Yamamura Y
    Cardiovasc Drugs Ther; 2011 Dec; 25 Suppl 1():S67-76. PubMed ID: 22120095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure.
    Costello-Boerrigter LC; Smith WB; Boerrigter G; Ouyang J; Zimmer CA; Orlandi C; Burnett JC
    Am J Physiol Renal Physiol; 2006 Feb; 290(2):F273-8. PubMed ID: 16189291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials.
    Miyazaki T; Fujiki H; Yamamura Y; Nakamura S; Mori T
    Cardiovasc Drug Rev; 2007; 25(1):1-13. PubMed ID: 17445084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of novel vasopressin receptor antagonists on renal function and cardiac hypertrophy in rats with experimental congestive heart failure.
    Bishara B; Shiekh H; Karram T; Rubinstein I; Azzam ZS; Abu-Saleh N; Nitecki S; Winaver J; Hoffman A; Abassi ZA
    J Pharmacol Exp Ther; 2008 Aug; 326(2):414-22. PubMed ID: 18467593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urocortin 2 inhibits furosemide-induced activation of renin and enhances renal function and diuretic responsiveness in experimental heart failure.
    Rademaker MT; Charles CJ; Nicholls MG; Richards AM
    Circ Heart Fail; 2009 Nov; 2(6):532-40. PubMed ID: 19919977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal effects of conivaptan, furosemide, and the combination in patients with chronic heart failure.
    Goldsmith SR; Gilbertson DT; Mackedanz SA; Swan SK
    J Card Fail; 2011 Dec; 17(12):982-9. PubMed ID: 22123359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicenter, randomized, double-blind, placebo-controlled study of tolvaptan monotherapy compared to furosemide and the combination of tolvaptan and furosemide in patients with heart failure and systolic dysfunction.
    Udelson JE; Bilsker M; Hauptman PJ; Sequeira R; Thomas I; O'Brien T; Zimmer C; Orlandi C; Konstam MA
    J Card Fail; 2011 Dec; 17(12):973-81. PubMed ID: 22123358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In chronic heart failure with marked fluid retention, the i.v. high doses of loop diuretic are a predictor of aggravated renal dysfunction, especially in the set of heart failure with normal or only mildly impaired left ventricular systolic function.
    De Vecchis R; Ciccarelli A; Ariano C; Cioppa C; Giasi A; Pucciarelli A; Cantatrione S
    Minerva Cardioangiol; 2011 Dec; 59(6):543-54. PubMed ID: 21330961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent aquaretic agent. A novel nonpeptide selective vasopressin 2 antagonist (OPC-31260) in men.
    Ohnishi A; Orita Y; Okahara R; Fujihara H; Inoue T; Yamamura Y; Yabuuchi Y; Tanaka T
    J Clin Invest; 1993 Dec; 92(6):2653-9. PubMed ID: 8254021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic and pharmacodynamic interaction between tolvaptan, a non-peptide AVP antagonist, and furosemide or hydrochlorothiazide.
    Shoaf SE; Bramer SL; Bricmont P; Zimmer CA
    J Cardiovasc Pharmacol; 2007 Aug; 50(2):213-22. PubMed ID: 17703139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current treatments and novel pharmacologic treatments for hyponatremia in congestive heart failure.
    Goldsmith SR
    Am J Cardiol; 2005 May; 95(9A):14B-23B. PubMed ID: 15847853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction.
    Udelson JE; McGrew FA; Flores E; Ibrahim H; Katz S; Koshkarian G; O'Brien T; Kronenberg MW; Zimmer C; Orlandi C; Konstam MA
    J Am Coll Cardiol; 2007 Jun; 49(22):2151-9. PubMed ID: 17543634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolvaptan improves left ventricular dysfunction after myocardial infarction in rats.
    Yamazaki T; Izumi Y; Nakamura Y; Yamashita N; Fujiki H; Osada-Oka M; Shiota M; Hanatani A; Shimada K; Iwao H; Yoshiyama M
    Circ Heart Fail; 2012 Nov; 5(6):794-802. PubMed ID: 22984091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats.
    Yamamura Y; Nakamura S; Itoh S; Hirano T; Onogawa T; Yamashita T; Yamada Y; Tsujimae K; Aoyama M; Kotosai K; Ogawa H; Yamashita H; Kondo K; Tominaga M; Tsujimoto G; Mori T
    J Pharmacol Exp Ther; 1998 Dec; 287(3):860-7. PubMed ID: 9864265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure.
    Cataliotti A; Boerrigter G; Costello-Boerrigter LC; Schirger JA; Tsuruda T; Heublein DM; Chen HH; Malatino LS; Burnett JC
    Circulation; 2004 Apr; 109(13):1680-5. PubMed ID: 15023890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medium term effects of different dosage of diuretic, sodium, and fluid administration on neurohormonal and clinical outcome in patients with recently compensated heart failure.
    Paterna S; Parrinello G; Cannizzaro S; Fasullo S; Torres D; Sarullo FM; Di Pasquale P
    Am J Cardiol; 2009 Jan; 103(1):93-102. PubMed ID: 19101237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 60.